猫皮屑集群免疫治疗效果与安全性评价

摘要/Abstract

摘要： 目的比较猫皮屑集群免疫治疗、常规免疫治疗、对症药物治疗的疗效,以及对比2种免疫治疗方案的不良反应,探讨评估猫皮屑集群免疫治疗的效果和安全性。方法招募猫皮屑过敏所致鼻炎伴或不伴哮喘的患者,用随机数表随机分配为集群免疫治疗组(集群组)、常规免疫治疗组(常规组)、对症药物治疗组(对照组)。在治疗开始前、治疗1个月后、治疗6个月后、治疗12个月后,分别记录并比较3组患者的鼻结膜炎症状评分,对症用药评分,联合症状用药评分,鼻结膜炎生活质量调查问卷评分,以及哮喘控制测试评分。同时评价免疫治疗注射相关局部与全身反应的发生率及严重程度。结果集群组的鼻结膜炎联合症状用药评分在治疗持续1个月(P=0.010)、6个月(P=0.001)、12个月(P=0.021)时均显著低于对照组;常规组在治疗12个月后,联合症状用药评分低于对照组(P=0.007)。集群组的鼻结膜炎生活质量调查问卷总分在治疗持续1个月(P=0.023)、12个月(P=0.015)时均显著优于对照组。在治疗开始1个月后,集群组的哮喘控制测试评分已优于对照组和常规组(P=0.050)。集群组与常规组免疫治疗注射所致局部(P=0.353)和全身反应(P>0.999)的发生率差异均无统计学意义。结论在本研究所观察的患者群体中,猫皮屑集群免疫治疗起效迅速,疗效确切,其注射相关不良反应的发生率与常规免疫治疗无差异。

关键词: 变应原免疫治疗, 集群免疫治疗, 猫皮屑, 安全性

Abstract: Objective To evaluate the efficacy and safety of cat dander cluster immunotherapy by comparing the efficacy of cat dander cluster immunotherapy, conventional immunotherapy and symptomatic drug therapy, as well as the adverse reactions of the two immunotherapy regimens. Methods Rhinitis patients with or without asthma caused by cat dander allergy were recruited and randomly assigned to the cluster immunotherapy group(cluster group), conventional immunotherapy group(conventional group), and symptomatic drug treatment group(control group). The rhinoconjunctivitis symptom score, symptomatic medication score, combined symptom medication score, rhinoconjunctivitis quality of life questionnaire score, and asthma control test score were recorded and compared among the three groups at baseline, 1 month of treatment, 6 months of treatment, and 12 months of treatment. Additionally, the incidence and severity of local and systemic reactions associated with immunotherapy injections were evaluated. Results The combined symptom medication score of rhinoconjunctivitis in the cluster group was significantly lower than that in the control group at 1 month(P=0.010), 6 months(P=0.001)and 12 months(P=0.021)of treatment. The combined symptom medication score in the conventional group was lower than that in the control group at 12 months of treatment(P=0.007). The rhinoconjunctivitis quality of life questionnaire score in the cluster group was significantly better than that in the control group at 1 month(P=0.023)and 12 months(P=0.015)of treatment. At 1 month of treatment, the asthma control test score of the cluster group was better than that of the control group and the conventional group(P=0.050). There was no difference in the incidence of local(P=0.353)or systemic reactions(P>0.999)induced by immunotherapy injections between the cluster group and the conventional group. Conclusions In the patient population observed in this study, cat dander cluster immunotherapy was rapid in onset and effective. There was no difference in the incidence of injection-related adverse reactions between the cluster and the conventional immunotherapy.

Key words: Allergen immunotherapy, Cluster immunotherapy, Cat dander, Safety

中图分类号:

R459.2

李丽莎,茹一,关凯,徐迎阳,边赛男,李论,潘周娴. 猫皮屑集群免疫治疗效果与安全性评价[J]. 山东大学耳鼻喉眼学报, 2026, 40(6): 1-9.

LI Lisha, RU Yi, GUAN Kai, XU Yingyang, BIAN Sainan, LI Lun, PAN Zhouxian. Evaluation of the efficacy and safety of cat dander cluster immunotherapy[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(6): 1-9.

参考文献

[1] Durham S R, Shamji M H. Allergen immunotherapy: past, present and future[J]. Nat Rev Immunol, 2023, 23(5): 317-328. DOI: 10.1038/s41577-022-00786-1
[2] Shamji M H, Sharif H, Layhadi J A, et al. Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma[J]. J Allergy Clin Immunol, 2022, 149(3): 791-801. DOI: 10.1016/j.jaci.2022.01.016
[3] 庞冲, 边赛男, 张冰, 等. 儿童过敏性鼻炎粉尘螨特异性舌下免疫治疗短期疗效评估 [J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 70-74. DOI:10.6040/j.issn.1673-3770.0.2021.117
[4] Nakagome K, Nagata M. Allergen immunotherapy in asthma[J]. Allergol Int, 2024, 73(4): 487-493. DOI: 10.1016/j.alit.2024.05.005
[5] Yepes-Nuñez J J, Guyatt G H, Gómez-Escobar L G, et al. Allergen immunotherapy for atopic dermatitis: systematic review and meta-analysis of benefits and harms[J]. J Allergy Clin Immunol, 2023, 151(1): 147-158. DOI: 10.1016/j.jaci.2022.09.020
[6] Greiwe J, Bernstein J A. Accelerated/rush allergen immunotherapy[J]. Allergy Asthma Proc, 2022, 43(4): 344-349. DOI: 10.2500/aap.2022.43.210108
[7] Matz J, Golden D B K. Cluster immunotherapy: don't rush to judgment[J]. Ann Allergy Asthma Immunol, 2023, 130(5): 536-537. DOI: 10.1016/j.anai.2023.01.022
[8] Domínguez Estirado A, Sánchez-Machín I, Poza-Guedes P, et al. Cluster subcutaneous allergen immunotherapy as a sustainable practice towards net zero healthcare[J]. Clin Transl Allergy, 2023, 13(7): e12241. DOI: 10.1002/clt2.12241
[9] Subiza J, Feliú A, Subiza J L, et al. Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment[J]. Clin Exp Allergy, 2008, 38(6): 987-994. DOI: 10.1111/j.1365-2222.2008.02995.x
[10] Tabar A I, Echechipía S, García B E, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus[J]. J Allergy Clin Immunol, 2005, 116(1): 109-118. DOI: 10.1016/j.jaci.2005.05.005
[11] Quiralte J, Justicia J L, Cardona V, et al. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy[J]. Immunotherapy, 2013, 5(12): 1295-1303. DOI: 10.2217/imt.13.133
[12] Zhu H Q, Huang Z F, Liu T T, et al. Sensitization to furry animals in patients with suspected allergic disease in China: a multicenter study[J]. J Asthma Allergy, 2022, 15: 1701-1712. DOI: 10.2147/JAA.S390473
[13] Nelson H S. Standardized allergen extracts for allergen immunotherapy[J]. Allergy Asthma Proc, 2022, 43(4): 327-332. DOI: 10.2500/aap.2022.43.220015
[14] Reddel H K, Bacharier L B, Bateman E D, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes[J]. Eur Respir J, 2021, 59(1): 2102730. DOI: 10.1183/13993003.02730-2021
[15] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国变应性鼻炎诊断和治疗指南(2022年,修订版)[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(2): 106-129. DOI:10.3760/cma.j.cn115330-20211228-00828
[16] Pfaar O, Demoly P, van Wijk R G, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper[J]. Allergy, 2014, 69(7): 854-867. DOI: 10.1111/all.12383
[17] Alvaro-Lozano M, Akdis C A, Akdis M, et al. EAACI allergen immunotherapy user's guide[J]. Pediatr Allergy Immunol, 2020, 31(Suppl 25): 1-101. DOI: 10.1111/pai.13189
[18] Roberts G, Pfaar O, Akdis C A, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis[J]. Allergy, 2018, 73(4): 765-798. DOI: 10.1111/all.13317
[19] Cox L, Larenas-Linnemann D, Lockey R F, et al. Speaking the same language: the world allergy organization subcutaneous immunotherapy systemic reaction grading system[J]. J Allergy Clin Immunol, 2010, 125(3): 569-574, 574.e1-574.e7. DOI: 10.1016/j.jaci.2009.10.060
[20] 王成硕, 张伟, 王向东, 等. 变应性鼻炎屋尘螨变应原集群免疫治疗与常规免疫治疗的对照研究[J]. 中华耳鼻咽喉头颈外科杂志, 2011, 46(12): 981-985. DOI:10.3760/cma.j.issn.1673-0860.2011.12.004
[21] Layhadi J A, Lalioti A, Palmer E, et al. Mechanisms and predictive biomarkers of allergen immunotherapy in the clinic[J]. J Allergy Clin Immunol Pract, 2024, 12(1): 59-66. DOI: 10.1016/j.jaip.2023.11.027
[22] Nanda A, O'Connor M, Anand M, et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract[J]. J Allergy Clin Immunol, 2004, 114(6): 1339-1344. DOI: 10.1016/j.jaci.2004.08.049
[23] Schubert R, Eickmeier O, Garn H, et al. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy[J]. Int Arch Allergy Immunol, 2009, 148(3): 251-260. DOI: 10.1159/000161585
[24] 中国康复医学会变态反应性疾病康复专业委员会, 北京慢性病防治与健康教育研究会变态反应学专业委员会. 吸入变应原皮下注射集群免疫治疗专家共识[J]. 中华预防医学杂志, 2024, 58(12): 1825-1834. DOI:10.3760/cma.j.cn112150-20240928-00781
[25] Fan Q J, Liu X J, Gao J J, et al. Comparative analysis of cluster versus conventional immunotherapy in patients with allergic rhinitis[J]. Exp Ther Med, 2017, 13(2): 717-722. DOI: 10.3892/etm.2017.4032
[26] Yu J Q, Zhong N P, Luo Q, et al. Early efficacy analysis of cluster and conventional immunotherapy in patients with allergic rhinitis[J]. Ear Nose Throat J, 2021, 100(5): 378-385. DOI: 10.1177/0145561319863370
[27] Huang J Y, Zhang W, Xiang R, et al. The early-phase transcriptome and the clinical efficacy analysis in three modes of subcutaneous immunotherapy for allergic rhinitis[J]. World Allergy Organ J, 2023, 16(8): 100811. DOI: 10.1016/j.waojou.2023.100811
[28] Zhang L, Wang CS, Han DM, et al. Comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis[J]. Int Arch Allergy Immunol, 2009, 148(2): 161-169. DOI: 10.1159/000155747
[29] Chen J H, Orden T, Wang J X, et al. Risk of anaphylaxis in cluster vs standard subcutaneous multiallergen immunotherapy[J]. Ann Allergy Asthma Immunol, 2023, 130(5): 622-627. DOI: 10.1016/j.anai.2022.12.009
[30] Copenhaver C C, Parker A, Patch S. Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice[J]. Ann Allergy Asthma Immunol, 2011, 107(5): 441-447. DOI: 10.1016/j.anai.2011.06.026
[31] 李丽莎, 杨冬明, 关凯, 等. 集群免疫治疗应用于变应性鼻炎的安全性[J]. 中华临床免疫和变态反应杂志, 2019, 13(6): 511-515. DOI:10.3969/j.issn.1673-8705.2019.06.017
[32] 江玲, 敬梅, 谢柏梅. 变应原终点滴定在变态反应性疾病免疫治疗中的应用[J]. 西北国防医学杂志, 2009, 30(5): 381-382. DOI: 10.16021/j.cnki.1007-8622.2009.05.022

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed